Daniele Catalucci

Group leader @CNR and @Humanitas. Basic and Translational #CardiovascularResearch x novel #TherapeuticApproaches #Nanoparticle #DrugDelivery #CUPIDO_project

[Daniele Catalucci @DCatalucci]

A research position is available within a funded PRIN 2022 PNRR project entitled “A Chaperone Network Shapes Heart Resilience During Stress and Aging.” Join us to investigate the molecular mechanisms underlying chaperone protection in cardiac aging.

https://t.co/KF0j7I7jhn

[DZHK Germany @dzhk_germany]

DZHK Paper of the Month | Feb 2024 🥁🏆
From the 🫁 to the 🫀: Read about a novel peptide-based inhalation therapeutic for the treatment of #HeartFailure Congratulations to Alessio Alogna @dhzcharite & his team
https://t.co/ImfyjXJNUL

#CardioTwitter

[CNR Consiglio Nazionale delle Ricerche @CNRsocial_]

Prosegue la sperimentazione dell'innovativa formulazione inalatoria per il trattamento delle malattie cardiache messa a punto nell’ambito del @cupido_project. I risultati sono descritti da uno studio coordinato da #Cnr_Irgb e @ChariteBerlin
👇
https://t.co/UFI9y34Yod

@MC_Carro

[Daniele Catalucci @DCatalucci]

Dry powder inhalation technology for heart targeting applied to calcium phosphate nanoparticles loaded with active substances https://t.co/qzFms6Ll8A @GenScript

[Daniele Catalucci @DCatalucci]

Discovering #NanoPhoria, a cutting-edge and brand-new startup developing a revolutionary and promising #HeartFailure inhalation treatment. Claudio De Luca, our CEO, explains how. Spoiler alert: it's done by a non-viral, biomimetic nanocarrier technology.
https://t.co/f2kUl9H2PN

[Crwe World @CrweWorld]

Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platfo https://t.co/bI8HWpy8Zo

[EDUino robot-FABsussidiario @FABsussidiario]

La startup biotech NanoPhoria incassa un round 3,5 milioni https://t.co/2LiuKxUjF8

[CNR Consiglio Nazionale delle Ricerche @CNRsocial_]

NanoPhoria, società spin-off del #Cnr, ha ricevuto un investimento di 3,5milioni € da parte di @SofinnovaVC, una delle principali società europee di venture capital nel settore delle scienze della vita.
La società sarà presentata oggi a #Bioequity Milano
https://t.co/ufH5x18k5S

[BioCentury @BioCentury]

In its eighth disclosed investment from its Italy-focused Telethon fund, @SofinnovaVC has backed non-viral delivery company NanoPhoria with a €3.5M seed investment https://t.co/zqzlEwlfGL

[Sofinnova Partners @SofinnovaVC]

We are pleased to welcome NanoPhoria to our portfolio via a €3.5 million seed investment that will advance its pre-clinical stage treatment for heart failure. #biotech
https://t.co/8qRL4Ayvfd

[Daniele Catalucci @DCatalucci]

National Research Council (CNR) Institute of Genetic and Biomedical Research (IRGB) is #hiring a Research Position (either a junior or post- doctoral fellow)! #openposition https://t.co/vSSaVyODFC

[Michele_Miragoli @Michele_Miragol]

at the TecMedLab @UNIPR in collaboration with @CNRsocial_ and @HumanitasMilano we growth SiC semiconductive nanowires to reinstate impulse propagation in 5 hrs after myocardial infarction. See our work published on @NatureComms.
https://t.co/mJ5Ixi3exJ

[Daniele Catalucci @DCatalucci]

A #research_position is #available for either a junior or post-doctoral fellow. #Nanotherapeutic approaches for #COVID19 and #HeartFailure
#Milan #job #research #fellowship
https://t.co/popzg4je8a https://t.co/oqaXl2zYlX

[Circulation @CircAHA]

#ResearchLetter MicroRNA therapeutics in cardiology is limited by invasive administration. @DCatalucci et al. demonstrate a proof-of-concept inhalable nanoparticle microRNA delivery mechanism @CNRsocial_ @HumanitasMilano https://t.co/kAHFnCpp5v

[Daniele Catalucci @DCatalucci]

Nano-miR-133a Replacement #Therapy Blunts Pressure Overload–Induced #HeartFailure #DrugDelivery #cardio #ncRNA #microRNA #inhalation @cupido_project @EU_Commission https://t.co/KfCe3itLYE

[Farah Sheikh @FarahSheikhLab]

The Sheikh lab is recruiting postdocs to sunny #SanDiego with interest in molecular cardiology! Explore new methods to define therapeutic targets for cardiomyopathy--with focus on translation to industry! DM me! Please RT. #postdocjobs #phdjobs #academia #UCSD interested?@MrBeast

[Daniele Catalucci @DCatalucci]

@paolomicheli Bellissima sintonia di colori e arte. Dove la troviamo?

[Daniele Catalucci @DCatalucci]

Nano- and Micro-carrier Based #Cardiovascular Drug Delivery. A new Research Topic @FrontDrugDDS has been lunched
https://t.co/HULaVGiS2I
#DrugDelivery, #DrugDiscovery, #nano #micro #DrugSafety

[Daniele Catalucci @DCatalucci]

#Research Topic
The Role of Circulating Immune Mediators in the Crosstalk Between Cells of the Immune System and Cardiovascular Systems in CVDs ⁦@FrontImmunol⁩ https://t.co/cFVm6AMZ2U

[Daniele Catalucci @DCatalucci]

@cupido_project @PlumeStars @eufeps I’m continuously proud of our friends @cupido_project, very Passionate Researchers. Congratulations Eride!!! Well deserved